Committed to the Development of Proprietary Antiviral Peptides and Monoclonal Antibody for Treating Debilitating Infectious Diseases
Welcome to Enzolytics, Inc.
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to developing monoclonal antibody therapy and treating infectious diseases. Discover MoreOur Mission
Our mission is clear – to create effective and affordable therapeutics for treating infectious diseases that plague the world. This goal includes the development of therapeutics and monoclonal antibodies targeting infectious diseases, including the CoronaVirus. Our ultimate objective is to provide such therapeutics to improve health around the world.
Enzolytics, Inc. is a Texas-based biotech company committed to the development and commercialization of its proprietary proteins and monoclonal antibodies for the treatment of infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus, and diphtheria. The Company’s multiple therapeutics also are being developed to treat Rheumatoid Arthritis and certain forms of cancer. Our technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19.
